key: cord-1030496-1126jgj3 authors: Relph, Sophie; Thangaratinam, Shakila title: Maternal medicine in the COVID era date: 2021-03-18 journal: Best Pract Res Clin Obstet Gynaecol DOI: 10.1016/j.bpobgyn.2021.03.003 sha: 65fdc0ab5fc1b700a19489ec1f0ce8484a7a10c2 doc_id: 1030496 cord_uid: 1126jgj3 The COVID-19 pandemic has directly and indirectly impacted on pregnant women with co-morbidities or antenatal medical complications, through vulnerability to the severe effects of COVID-19 and service reconfiguration. Women with diabetes or hypertension in pregnancy are at higher risk of admission to intensive care, need for invasive ventilation and death from COVID-19. Suggested service modifications specific to maternal medicine services include home measurement of blood glucose or blood pressure, the use of risk calculators, adaptations to screening criteria for gestational diabetes and monitoring of obstetric cholestasis. Neither the added risk of COVID-19 on pregnant women with medical co-morbidities, nor the impact of maternal medicine service modifications has yet been established. Maternal medicine, which focuses on the care of pregnant women with pre-existing comorbidities or medical complications which arise during pregnancy, is critical during the COVID-19 (coronavirus disease) pandemic. These women, who are at high risk of complicated pregnancy, are affected by the pandemic both directly and indirectly. Pregnant women with pre-existing comorbidities such as hypertension and diabetes are more likely to have severe COVID-19 than women at low risk; they are at increased risk of death, of being admitted to the intensive care unit, and of needing invasive ventilation [1] . The indirect effects of the pandemic on the maternal and perinatal health of high-risk pregnant women result from changes in delivery of antenatal, intrapartum and postpartum care. Health services have been reconfigured in response to staffing crises caused by staff infected with or exposed to SARS-CoV-2 or the redeployment of staff and resources, and change in guidelines to minimise risk of COVID-19 to pregnant women. Furthermore, access to care could also be compromised by country-wide policies involving 'stay at home' (lock-down) guidance and recommendations for those who are most vulnerable to SARS-CoV2 infection to shield (not to leave home unless absolutely essential) [2, 3] . In this review, we summarise the current evidence on the magnitude of COVID-19's impact on high-risk pregnant women and their babies, and service modifications proposed by national guidelines for the care of such women during the pandemic (service modifications summarised in J o u r n a l P r e -p r o o f Table 1 ). Many of the service modifications have been pragmatic given the urgency of the scenario. Reversion to pre-pandemic care is recommended as soon as safe. J o u r n a l P r e -p r o o f • Offer in-person appointments to coincide with appointments for other investigations, such as fetal ultrasound or blood tests [4] . • Where investigations and examinations are not necessary, offer consultation via virtual means [4] . • All women should have a venous-thromboembolism risk assessment at the first antenatal appointment, and repeated throughout pregnancy, particularly when the woman's situation changes [5, 6] . • Offer self-monitoring of blood pressure at home. Provide information on thresholds at which to seek a medical opinion. Clinician to review recorded measurements virtually [4] . • Where available, offer home urinalysis [4] . • Where pre-eclampsia is suspected, the initial assessment must be conducted in-person [4] . • Placental-growth factor-based testing should be offered to women with suspected pre-eclampsia where available to guide decisions on diagnosis, hospital admission and time of birth [4] . • Consider the use of calculators to determine the risk of a woman developing pre-eclampsia complications [7, 8] . • Consider offer of alternative screening pathways to reduce risk of SARS-CoV-2 transmission. Alternative regimens available in the UK [4] , Australia [9] , and Canada [10] . • Consider screening based on risk prediction tool results [4] . • Blood glucose measurements taken at home can be reviewed during a virtual consultation for the majority of women [4] . • Repeat prescriptions for medications of glucose monitoring equipment should be obtained in the community [4] . • Also offer home blood pressure monitoring for women with pre-existing diabetes, where equipment is available [4] . • Provide clear guidance on self-help and when to seek medical advice for high or low blood glucose measurements [4] . J o u r n a l P r e -p r o o f 6 Cardiac disease • Pregnant women with significant congenital or acquired heart disease are vulnerable to the severe effects of COVID-19 and so efforts must be made to protect them from infection [2, 3] . • Home monitoring of the international normalised ratio (INR) is possible, and where available should be prioritised amongst pregnant women to those with metallic heart valves [4] . • Individuals with asthma are advised to continue their regular medications including inhaled corticosteroids, in line with their personalised action plan [11, 12] . • Individuals with cystic fibrosis and interstitial lung disease are vulnerable to the severe effects of COVID-19 and so efforts must be made to protect them from infection [2, 3] . • Women with cystic fibrosis and COVID-19 are encouraged to carry out airway clearance procedures whist alone in a well-ventilated room, wherever possible, given that airway clearance procedures are likely to be aerosol generating [13] . • There is international disagreement on whether nebulisers are aerosol-generating and therefore whether healthcare workers administering them require the highest level of personal protective equipment (including filtering face piece masks) [11, 14, 15] . • Pregnant women with homozygous sickle cell disease (SCD) are vulnerable to the severe effects of COVID-19 so efforts must be made to protect them from infection [2, 3] . • Clinicians should have a low threshold to offer SARS-CoV-2 testing to women with SCD, who may present atypically. • For women using low molecular weight heparin, anti-factor Xa monitoring is essential only for those with antithrombin deficiency, or those with a metallic heart valve [4] . • Individuals with chronic kidney disease (CKD) are at higher risk of becoming severely unwell with COVID-19 so efforts must be made to protect them from infection [2, 3] . • The frequency of monitoring for deteriorating renal function in adults with CKD or a renal transplant should be maintained for pregnant women during the pandemic. • Individuals taking immunosuppressant medications are at increased risk of becoming severely unwell with COVID-19 so efforts must be made to protect them from infection [2, 3] . • Immunosuppressant medications should be continued as standard for pregnant women who do not have acute infection. • Monitoring bile acid levels can be limited to each in-person antenatal appointment at or after 34 weeks' gestation for pregnant women with persistent itch (where other causes have been excluded) [4] . • Women with bile acids <100µmol/l may be offered elective birth at 39 weeks' gestation, but women with bile acids of 100µmol/l of greater should be counselled re. the risks and benefits of elective birth at 35-36 weeks' gestation, or at the time of diagnosis if this occurs later [4] . • Women with mild symptoms may be signposted to local or online sources for self-help [4] . • Pregnant women who express more worrying symptoms, such as suicidal ideation or hallucinations, should be referred immediately for psychiatric review [6] . J o u r n a l P r e -p r o o f Hypertension affects approximately 10% of pregnant women [16] , including both chronic hypertensive diseases, which usually pre-date pregnancy, and the gestational disorders such as preeclampsia and gestational hypertension. Pregnant women with chronic hypertension are twice as likely to be affected by severe COVID-19 as non-pregnant reproductive aged women without chronic hypertension [1] . In non-pregnant adults, it is hypothesised that this association may be mediated through up-regulation of the angiotensin converting enzyme (ACE)-2 in individuals taking reninangiotensin-aldosterone inhibitors [17] , but there is lack of evidence to explain the association in pregnancy. A few observational studies have suggested that COVID-19 disease either causes, or can manifest itself as, severe pre-eclampsia with the women's serum biochemistry findings similar to those seen in HELLP syndrome (haemolysis, elevated liver enzymes and low platelets), but with a normal sFlt-1/PlGF ratio [18, 19] . In the living systematic review on COVID-19 in pregnancy, an association was observed with pre-eclampsia diagnosis and severe COVID-19 [1] , but the included studies were small with significant bias [20] . Antenatal guidelines on monitoring blood pressure for pregnant women with hypertensive disorders commonly recommend frequent in-person appointments, including twice weekly appointments for women in whom the blood pressure is not controlled (target <135/80mmHg) [7, 21] . Self-monitoring blood pressure at home can reduce the risk of SARS-CoV-2 transmission to both pregnant women and healthcare staff during in-person clinic appointments [22] . A feasibility study found the intervention to be acceptable to women and well-adhered to, without adversely affecting mean systolic blood pressure [23] . There is an ongoing randomised trial on self-monitoring of blood pressure in pregnancy compared to usual care in hospital [24] . Self-monitoring of blood pressure still requires clinicians to review the blood pressure measurements (either in-person or remotely), arrange further fetal ultrasound assessment and maternal blood tests, to ensure timely recognition of maternal or fetal complications. Both the sFlt-1/PlGF ratio and the PlGF test have been recommended for use during the pandemic, to aid discrimination between pre-eclampsia and the other hypertensive disorders of pregnancy, thereby guiding clinical care decisions and potentially supporting clinicians to avoid hospital admission, where it is not required [4, 7] . Clinicians are also advised to use risk calculators, to determine the risk of complications [4, 25] . The PREP-S risk calculator can be used to determine the risk of serious maternal complications or preterm birth prior to 34 weeks' gestation [8] . Prevalence of diabetes in pregnancy is population-specific, because of differences in risk factors, such as obesity or Asian ethnicity. In the UK, up to 5% of pregnant women have diabetes (including gestational). Of these, approximately 12·5% (0.6% overall) have pre-existing type 1 or type 2 diabetes [26] . Diabetes is associated with an increased risk of severe COVID-19 in pregnancy [1, 27] . This association is complex and likely contributed to by the associated characteristics (being overweight or obese, or of Black or Asian ethnicity), and a pro-inflammatory and pro-thrombotic corporal environment [28] . COVID-19 might cause deterioration in diabetic control, through binding of SARS-CoV-2 to ACE-2 receptors in pancreatic β-cells. Hyperglycemia at the time of hospital admission with COVID-19 has been found to be predictive of worse prognosis in non-pregnant individuals with diabetes [28] . Gestational diabetes mellitus (GDM) also appears to be an independent risk factor for severe COVID-19 [1] . Furthermore, individuals at risk of GDM have been affected internationally by modifications to GDM screening criteria [4, 9, 10, 29] . In usual practice, GDM screening is either offered universally, or only to those women with risk factors, and centres around an offer of an oral glucose tolerance test (OGTT), with varying criteria for diagnosis [26, 30] . These pre-pandemic screening strategies should continue to be adhered to where safe to do so during the pandemic, but it is acknowledged that an OGTT may require a prolonged hospital visit, where social distancing can be difficult in small waiting areas or staffing resources may be constrained. Where local prevalence of SARS-CoV-2 means that the risk of transmission to pregnant women is high, modified screening strategies allow the blood draw for GDM screening to be conducted at the same time as a draw for other antenatal bloods, and include screening with both glycated haemoglobin A1c (HbA1c) and fasting or random serum glucose [7, [22] [23] [24] . Validated personalised risk calculators can be used to target individuals at highest risk, and are most useful where universal screening is common practice [31] . Modified GDM screening strategies have been criticised because they result in under-diagnosis of GDM when compared to classic screening strategies [32] . This was acknowledged at the time of recommendation by the authors of the modified UK Royal College of Obstetricians and Gynaecologists (RCOG) screening strategy, but it was also expected that the women with missed diagnosis were at lowest risk of adverse perinatal outcomes [4] . The benefit to women in terms of preventing infection with SARS-CoV-2 is not known and cannot be easily measured. For women with diabetes in pregnancy, ongoing management should focus on lifestyle advice, blood glucose surveillance and control, and monitoring and management of perinatal complications associated with diabetes [29] . Antenatal education sessions which target lifestyle interventions may be offered through virtual means, although consideration should be given to those who do not have access to video conferencing software, or sufficient internet bandwidth, to prevent inequity of provision. At present, published prediction models for the risk of complications are subject to bias and have not been externally validated; these are therefore not currently recommended for use outside of a research setting [33] . It is expected that monitoring for hyperglycemia and medication titration can be offered to most women via virtual means (video or telephone call) [29] , but in-person care is still indicated in cases where remote communication is challenging, care is complex, or further investigations such as fetal growth surveillance are indicated. Clinicians are advised to arrange face-to-face care to coincide with other in-person appointments, to reduce the number of clinic visits to which each woman is invited [4] . Cardiac conditions in pregnancy (other than hypertension) are rare [34] , but remain the most common cause of direct maternal death in developed countries [35] . COVID-19 is more severe in individuals with cardiovascular disease and may also cause myocardial injury in those without preexisting disease [36] . Such myocardial injury has a varied phenotype (including those of acute coronary syndrome, arrhythmia, cardiogenic shock and myocarditis) and is associated with higher rates of death from COVID-19 [36, 37] . Whether the risk of severe disease is also true for pregnant women remains unknown because co-existent cardiac disease and COVID-19 in pregnancy is rare and case numbers are too small to prove an association with severe disease. However the UK Maternal Cardiology Society has published a list of cardiac conditions, that are believed to put pregnancy women at highest risk [38] . These have been replicated in Box 1. Further care should be arranged in conjunction with intensivists and cardiologists, should include an echocardiogram to assess cardiac function, and should occur in a setting where the pregnant woman can be intensively monitored and rapid deterioration quickly recognised [37] . Given that pregnant women with pre-existing cardiac disease are at high risk of maternal complications during pregnancy, including mortality, antenatal care should be prioritised for this group of women and continue according to best practice, as far as possible. Asthma is the most common respiratory disease affecting pregnant women. Despite early concerns that individuals with asthma were likely to be vulnerable to the severe effects of COVID-19 [2, 3] , this has not been proven in systematic reviews of observational literature for either the pregnant or non-pregnant population [1, 41] . Individuals with asthma are advised to continue their regular medications including inhaled corticosteroids, in line with their personalised action plan [11, 12] . Individuals with cystic fibrosis and interstitial lung disease are at high risk of developing severe COVID-19, regardless of whether they are pregnant [2, 42] . NICE have published rapid guidelines for the care of individuals with both of these respiratory conditions during the pandemic [13, 43] . Women with cystic fibrosis and COVID-19 are encouraged to carry out airway clearance procedures whist alone in a well-ventilated room, wherever possible, given that airway clearance procedures are likely to be aerosol generating. There is international disagreement as to whether nebulised medications represent aerosol-generating procedures, for which a higher level of personal protective equipment (PPE) is recommended for anyone present in the room at the time. UK guidelines suggest that nebulisers only release particles of medication and do not recommend high level PPE (including a filtering facepiece mask, visor and surgical gown) [11, 14] . Guidelines from the USA suggest that nebulisers may release infectious aerosols although it is unknown whether it is this, or close contact with the patient, which raises the risk of SARS-CoV-2 transmission [15] . All individuals with respiratory conditions who use equipment for their respiratory care (e.g. mouth pieces, spacers and peak flow meters) are encouraged to wash their hands before and after use, and to clean their equipment regularly with a detergent [11, 13] . Routine respiratory investigations which are not urgently required to guide further management of the woman's condition, e.g. pulmonary function tests or bronchoscopy, should be reviewed and possibly deferred if they cannot be offered safely, particularly in areas affected by high prevalence of COVID-19 or healthcare professional shortages [11, 13, 43] . Differentiating between acute presentations of respiratory disease deterioration and COVID-19 in individuals with respiratory co-morbidities can be difficult, especially for individuals taking immunosuppressant medications, in whom COVID-19 may present atypically [11, 43] . Where there is clinical uncertainty, infection control measures should be adhered to as if the individual has COVID-19, until virology investigations are conclusive to the contrary. During flu season, there is international concern that the double threat of respiratory viruses may present further pressure on health services, although it is acknowledged that national infection control restrictions (e.g. 'lockdown', social distancing and wearing face coverings) may also reduce transmission of influenza viruses [44] . Nevertheless, pregnant women are at increased risk of becoming severely unwell from influenza [45] , and vaccination is safe and effective [46] . It is therefore strongly recommended that all pregnant women are offered a flu virus vaccine during the local flu season. Of the common haematological disorders affecting pregnant women, homozygous sickle cell disease (SCD) is the most important, in terms of increasing the risk of severe COVID-19 [47] . For this reason, women with SCD should be protected from the risk of transmission, with routine appointments carried out virtually if safe and possible to do so. Women should be advised to regularly check their temperature at home, and to speak to their haematologist if febrile [48] . Women with mild sickle pain should try to manage this at home with oral analgesia, but clinicians should have a low threshold to arrange for the woman to be seen by her haematologist and be offered SARS-CoV-2 testing. In those who do have COVID-19, a multi-disciplinary team of clinicians (obstetricians, haematologists, intensivists where required) should be vigilant to the signs and symptoms of acute chest crisis (thrombocytopenia, acute kidney injury, hepatic dysfunction and/or altered mental status), which can overlap with those of COVID-19. Sickle cell disease increases the risk of developing thrombo-embolism in pregnancy, as does COVID-19, so a timely offer of thromboprophylaxis is essential [5] . It is acknowledged that COVID-19 is associated with a high rate of thrombotic complications (pulmonary microvascular thromboses and hospital-acquired venous thromboembolism [VTE]) [49] , believed to be caused by a combination of inflammation, endothelial dysfunction, platelet activation, and stasis. Since pregnancy itself is pro-thrombotic, pregnant women are expected to be at equal or higher risk than the non-pregnant population [50] . In a UK review of COVID-19 associated maternal deaths during the first wave of the pandemic, the death of at least one of 11 women with COVID-19 was caused by VTE (it was also suspected as the cause of another death) [51] . All pregnant women should have a VTE risk assessment conducted in early pregnancy, and those at significant risk commenced on thromboprophylaxis according to local protocols [5] . Risk should be re-assessed during pregnancy, particularly when the woman's situation changes, for example if she has reduced mobility during a period of self-isolation, or a mild case of COVID-19. Thromboprophylaxis should also be offered at standard doses to all pregnant women hospitalised with COVID-19 and consideration should be given to increasing the dose for women receiving advanced respiratory support [4, 52, 53] . D-dimer levels are normally elevated in healthy pregnancy, and more so with COVID-19; this acute elevation is not necessarily indicative of thromboembolism [54] , so pregnant women with suspected VTE should be primarily investigated with imaging, as recommended by nonpandemic guidance [55] . Severe COVID-19 is associated with acute kidney injury (AKI) in at least a quarter of nonpregnant adults [56] . SARS-CoV-2 may directly injure the renal tubules, or cause AKI through cytokine storm or fluid imbalance [57] . In pregnancy, the cause of AKI must be distinguished from other common causes, including obstructive nephropathy and pre-eclampsia. Medications which may contribute to AKI should be stopped and pregnant women admitted to hospital with COVID-19 should have their fluid balance monitored, taking into account insensible losses from fever and tachypnoea, and intravenous or oral fluids targeting euvolaemia administered [58] . Individuals with chronic kidney disease (CKD) are at higher risk of becoming severely unwell with COVID-19 [2, 3] . This association is not established in pregnancy; however, pregnant women with CKD should observe the same caution as non-pregnant adults. Whilst reducing the frequency of biochemical monitoring for non-pregnant individuals with CKD during the pandemic has been advised [59] , such a strategy is not advisable in pregnancy, where physiological changes to the cardiovascular system may destabilise CKD. However, pregnant women with CKD may be able to self-monitor their blood pressure at home (as per section on hypertension) and this may reduce the frequency of appointments, and hence the risk of infection. Pregnant women may take immunosuppressant medications for a variety of reasons, including inflammatory bowel disorders, rheumatological disorders or as recipients of solid organ transplants. Individuals taking immunosuppressant medications are at increased risk of becoming severely unwell with COVID-19 [2, 3] . Immunosuppressant medications should be continued as standard for pregnant women who do not have acute infection. Where possible (when examination or investigations not required or can safely be deferred), these women should be reviewed via remote consultation, to reduce the risk of becoming infected with SARS-CoV-2 during a clinic visit. Both women and clinicians should be aware that COVID-19 may present atypically in individuals on immunosuppression, including absence of fever [60] . [4] . The COVID-19 pandemic has resulted in an increased level of anxiety and depressive symptoms for the whole population, but for pregnant women to a greater extent [63] . Anxieties are caused by fear of being infected and the potential effect on mother and baby, social isolation and reduced support from wider family and friends, the socioeconomic impacts of national lockdowns and major changes in access to medical care [64] . The pandemic is expected to reduce options for access to mental health services [65] , meaning that deterioration in existing mental illness may go unnoticed, and psychiatric care may be delayed. Pregnant women should therefore be asked about their mental wellbeing during every contact with a healthcare professional. Women with mild symptoms may be signposted to local or online sources for self-help. Pregnant women who express more worrying symptoms, such as suicidal ideation or hallucinations, should be referred immediately for psychiatric review [6] . Pregnant women with medical co-morbidities or complications of pregnancy have been both Not applicable. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. • Antenatal and postnatal care should continue to be provided during the pandemic according to best practice guidelines, where safe and feasible to do so. • Pregnant women with significant co-morbidities should be cared for during pregnancy by a multidisciplinary team, including an obstetrician with a specialist interest in maternal medicine, and a physician with knowledge of the subject area. • Clinicians should be aware of the list of medical co-morbidities for which there is an increased risk (or hypothetical risk) of the individual becoming severely unwell with COVID- J o u r n a l P r e -p r o o f • For women at highest risk of becoming severely unwell with COVID-19, it may be possible to convert some clinic appointments to remote consultations, particularly where examination or investigation are not indicated, to reduce the risk of SARS-CoV-2 infection. Investigations which cannot be arranged at home should be scheduled together where possible, to avoid repeated hospital visits. • Both COVID-19 and reduced mobility increase the risk of thromboembolic complications over and above the risk attributed to pregnancy and co-morbidities. Thromboprophylaxis should be offered to all pregnant women admitted to hospital with COVID-19. • Pregnant women have an increased risk of developing symptoms of anxiety or depression during the pandemic and should be asked about their mental wellbeing at every contact with a healthcare professional. • Large prospective studies are required to compare obstetric outcomes in high-risk pregnant women with and without COVID-19, in order to identify the added risk due to infection with SARS-CoV-2 • Randomised trials on various pharmacological treatments for COVID-19 will need to include high-risk pregnant women, who are most at risk of severe complications • Robust studies are needed to determine the indirect impact of change in guidelines and practices for antenatal care of high-risk pregnant women due to the pandemic • Interventions to facilitate remote care of high-risk pregnant women need to be codeveloped with patient and public involvement groups to ensure that these are acceptable, feasible and equitable -The COVID-19 pandemic has directly and indirectly impacted on pregnant women with comorbidities or antenatal medical complications, through vulnerability to the severe effects of COVID-19 and service reconfiguration. -Women with diabetes or hypertension in pregnancy are at higher risk of admission to intensive care, need for invasive ventilation and death from COVID-19. -Suggested service modifications specific to maternal medicine services include home measurement of blood glucose or blood pressure, the use of risk calculators, adaptations to screening criteria for gestational diabetes and monitoring of obstetric cholestasis. -Neither the added risk of COVID-19 on pregnant women with medical co-morbidities, nor the impact of maternal medicine service modifications has yet been established. Maternal and perinatal outcomes in pregnant and recently pregnant women with coronavirus disease 2019: living systematic review and meta-analysis Guidance on shielding and protecting people who are clinically extremely vulnerable from COVID-19 2020 College of Obstetricians & Gynaecologists. Guidance for maternal medicine services in the evolving coronavirus (COVID-19) pandemic 2020 Royal College of Obstetricians & Gynaecologists. Reducing the Risk of Venous Thromboembolism during Pregnancy and the Puerperium Royal College of Obstetricians & Gynaecologists. Coronavirus (COVID-19) infection and pregnancy 2020 Hypertension in pregnancy: diagnosis and management Prediction of complications in early-onset preeclampsia (PREP): development and external multinational validation of prognostic models Diagnostic testing for gestational diabetes mellitus (GDM) during the COVID 19 pandemic. Antenatal and postnatal testing advice 2020 Urgent update -temporary alternative screening strategy for gestational diabetes screening furing the COVID-19 pandemic 2020 COVID-19 rapid guideline: severe asthma 2020 Addressing therapeutic questions to help Canadian physicians optimize asthma management for their patients during the COVID-19 pandemic National Institute for Health and Care Excellence COVID-19: Infection, prevention and control guidance 2020 Clinical Questions about COVID-19: Questions and Answers Diagnosis and management of hypertension in pregnancy: summary of updated NICE guidance COVID-19 and arterial hypertension: Hypothesis or evidence? Pre-eclampsia-like syndrome induced by severe COVID-19: a prospective observational study Is COVID-19 a risk factor for severe preeclampsia? Hospital experience in a developing country Can COVID-19 in pregnancy cause pre-eclampsia? BJOG The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice 03-30-self-monitoring-of-blood-pressure-in-pregnancy A randomised controlled trial of blood pressure selfmonitoring in the management of hypertensive pregnancy. OPTIMUM-BP: A feasibility trial Blood pressure monitoring in high-risk pregnancy to improve the detection and monitoring of hypertension (the BUMP 1 and 2 trials): protocol for two linked randomised controlled trials Hypertension in pregnancy: diagnosis and management Diabetes in pregnancy: management from preconception to the postnatal period Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study COVID-19 in people with diabetes: understanding the reasons for worse outcomes International Association of Diabetes, Pregnancy Study Groups Consensus P, Metzger BE, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy External validation of prognostic models to predict risk of gestational diabetes mellitus in one Dutch cohort: prospective multicentre cohort study Testing for gestational diabetes during the COVID-19 pandemic. An evaluation of proposed protocols for the United Kingdom, Canada and Australia The Unrealised Potential for Predicting Pregnancy Complications in Women with Gestational Diabetes: A Systematic Review and Critical Appraisal Global cardiac risk assessment in the Registry Of Pregnancy And Cardiac disease: results of a registry from the European Society of Cardiology Saving Lives, Improving Mothers' Care Current Perspectives on Coronavirus Disease 2019 and Cardiovascular Disease: A White Paper by the JAHA Editors COVID-19 rapid guideline: acute myocardial injury 2020 Statement on the risk assessment of pregnant women with heart disease during the COVID 19 pandemic 2020 Myocardial injury associated with coronavirus disease 2019 in pregnancy New-Onset myocardial injury in COVID-19 Pregnant Patients: A Case Series of 15 Patients Asthma in COVID-19 Hospitalizations: An Overestimated Risk Factor? Guidance on shielding and protecting people who are clinically extremely vulnerable from COVID-19 2020 COVID-19 rapid guideline: interstitial lung disease 2020 Double threat of COVID-19 and influenza. The Lancet Respiratory Medicine Pregnancy as a risk factor for severe outcomes from influenza virus infection: A systematic review and meta-analysis of observational studies Influenza Vaccine Effectiveness in Preventing Influenza-associated Hospitalizations During Pregnancy: A Multi-country Retrospective Test Negative Design Study Coronavirus Disease among Persons with Sickle Cell Disease Sickle cell disease and COVID-19: provider advisory 2020 Incidence of venous thromboembolism in hospitalized patients with COVID-19 A critical review of the pathophysiology of thrombotic complications and clinical practice recommendations for thromboprophylaxis in pregnant patients with COVID-19 Learning from SARS-CoV-2-related and associated maternal deaths in the UK 2020 COVID-19 Coagulopathy in Pregnancy: Critical Review, Preliminary Recommendations and ISTH Registry -Communication from the ISTH SSC for Women's Health COVID-19 rapid guideline: reducing the risk of venous thromboembolism in over 16s with COVID-19 2020 Laboratory Abnormalities in Pregnant Women with Novel Coronavirus Disease Royal College of Obstetricians & Gynaecologists. Thrombosis and Embolism during Pregnancy and the Puerperium: Acute Management ICNARC. Report on COVID-19 in critical care 2020 COVID-19 Pandemic and Pregnancy in Kidney Disease COVID-19 rapid guideline: acute kidney injury in hospital 2020 COVID-19 rapid guideline: chronic kidney disease 2020 COVID 19 rapid guideline: renal transplantation 2020 Royal College of Obstetricians & Gynaecologists. Obstetric Cholestasis Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses COVID-19 pandemic and maternal mental health: a systematic review and meta-analysis Pregnant women voice their concerns and birth expectations during the COVID-19 pandemic in Italy Mental Health and the Covid-19 Pandemic The authors wish to thank their co-authors on the RCOG document: 'Guidance for maternal medicine services in the coronavirus (COVID-19) pandemic' for their expertise in writing recommendations for the care of pregnant women with co-morbidities and medical complications of pregnancy, and reconfiguration of maternal medicine services during the COVID-19 pandemic.